Shigeta, Keigo http://orcid.org/0000-0003-4300-4231
Suzuki, Kentaro
Matsumaru, Yuji
Takeuchi, Masataka
Morimoto, Masafumi
Kanazawa, Ryuzaburo
Takayama, Yohei
Kamiya, Yuki
Okubo, Seiji
Hayakawa, Mikito
Ishii, Norihiro
Koguchi, Yorio
Ota, Takahiro
Takigawa, Tomoji
Inoue, Masato
Naito, Hiromichi
Hirano, Teruyuki
Kato, Noriyuki
Ueda, Toshihiro
Akaji, Kazunori
Iguchi, Yasuyuki
Miki, Kazunori
Tsuruta, Wataro
Fujimoto, Shigeru
Enomoto, Masaya
Aoyama, Jiro
Nakano, Tomoyuki
Kimura, Kazumi
,
Funding for this research was provided by:
Japanese Society for Neuroendovascular Therapy
Article History
Received: 20 March 2021
Accepted: 5 August 2021
First Online: 8 September 2021
Declarations
:
: K. Shigeta, K. Suzuki, M. Morimoto, R. Kanazawa, Y. Takayama, S. Okubo, M. Hayakawa, N. Ishii, Y. Koguchi, T. Ota, T. Takigawa, M. Inoue, H. Naito, N. Kato, T. Ueda, K. Akaji, K. Miki, W. Tsuruta, S. Fujimoto, M. Enomoto, J. Aoyama and T. Nakano declare that they have no competing interests. K. Kimura received lecture fees from Bristol Myers Squibb, Nippon Boehringer Ingelheim, Bayer Healthcare, and Daiichi Sankyo; research funding from Nippon Boehringer Ingelheim, Daiichi Sankyo, Pfizer Japan, Medtronic, and Teijin Pharma; and personal funding from the 38th Mihara Cerebrovascular Disorder Research Promotion Fund. M. Takeuchi received lecture fees from Stryker. Shigeru Fujimoto received lecture fees from Nippon Boehringer Ingelheim, Daiichi Sankyo, Pfizer Japan, Bristol Myers Squibb Co. Ltd., Bayer Healthcare, and Takeda Pharmaceutical. T. Hirano received lecture fees from Bayer Healthcare, Daiichi Sankyo, Nippon Boehringer Ingelheim, Bristol Myers Squibb, Medtronic, Sanofi, Otsuka Pharmaceutical, Mitsubishi Tanabe Pharma, CSL Behring, Astellas Pharma, and Pfizer Japan. Y. Iguchi received lecture fees from Bayer Healthcare, Pfizer Japan, Nippon Boehringer Ingelheim, Takeda Pharmaceutical, Otsuka Pharmaceutical, and Daiichi Sankyo; and research funding from Sanofi. Y. Kamiya received lecture fees from Daiichi Sankyo; and research funding from Bristol Myers Squibb. Y. Matsumaru received lecture fees from Medtronic, Stryker, Sanofi, Daiichi Sankyo, Otsuka Pharmaceutical, and Biomedical solutions.
: The SKIP study was approved by the local institutional review boards, and written informed consent was obtained from all study participants. Because this study used existing anonymized information from the SKIP study, written informed consent from the study subjects was exempted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subject in Japan. Consent to publish: not applicable.